Valuation: Madrigal Pharmaceuticals, Inc.

Market Cap 10.8B 9.38B 8.76B 8.04B 15.16B 1,029B 15.43B 103B 40.46B 513B 40.56B 39.66B 1,693B P/E 2026 *
-74x
P/E 2027 * 74.2x
Enterprise Value 10.27B 8.93B 8.34B 7.65B 14.43B 979B 14.68B 98.28B 38.49B 488B 38.59B 37.73B 1,611B EV / Sales 2026 *
6.75x
EV / Sales 2027 * 4.61x
Free-Float
93.92%
Yield 2026 *
-
Yield 2027 * -
1 day+3.14%
1 week-12.56%
Current month+3.14%
1 month-8.97%
3 months-7.07%
6 months-0.09%
Current year-17.23%
1 week 447.01
Extreme 447.01
561.15
1 month 447.01
Extreme 447.01
569.44
Current year 416.21
Extreme 416.21
598.79
1 year 299.17
Extreme 299.17
615
3 years 119.76
Extreme 119.7604
615
5 years 52.33
Extreme 52.33
615
10 years 7.08
Extreme 7.08
615
Manager TitleAgeSince
Chief Executive Officer 59 08/09/2023
Director of Finance/CFO 62 11/03/2024
Chief Tech/Sci/R&D Officer 58 21/04/2025
Director TitleAgeSince
Director/Board Member 74 01/07/2016
Director/Board Member 68 11/08/2016
Director/Board Member 64 27/06/2019
Date Insider Type Main position Quantity % Market Cap.
20/7/26 Sell

Chief Executive Officer

-2,500 0.0108%
17/6/26 Free

Director

1,220 0.0053%
23/2/26 Fiscal year

Director

5,000 0.0220%
Change 5-day change 1-year change 3-year change Capi.($)
+3.14%-12.56%+54.43%+149.39% 10.8B
+0.05%+2.80%+38.17%+74.12% 56.54B
-3.06%-10.22%+23.62%+58.59% 53.6B
+1.84%+1.27%-16.16%-13.50% 22.91B
-0.15%-6.00%-11.50%+344.47% 21.37B
+0.15%-0.77%+23.76%-11.52% 20.27B
-0.67%-1.73%+33.09%-31.09% 17.56B
-1.45%-7.24%+17.67%+563.14% 14.75B
+9.91%+2.64%+188.84%+326.19% 13.53B
+3.83%-1.34%+49.58%+165.22% 13.33B
Average +1.36%-3.11%+40.15%+162.50% 24.47B
Weighted average by Cap. +0.27%-2.25%+32.44%+123.18%

Financials

2026 *2027 *
Net sales 1.52B 1.32B 1.24B 1.13B 2.14B 145B 2.18B 14.57B 5.71B 72.38B 5.72B 5.59B 239B 2.14B 1.86B 1.73B 1.59B 3B 204B 3.05B 20.43B 8B 101B 8.02B 7.84B 335B
Net income -184M -160M -149M -137M -258M -17.53B -263M -1.76B -689M -8.74B -691M -675M -28.83B 200M 174M 162M 149M 281M 19.06B 286M 1.91B 749M 9.51B 751M 735M 31.36B
Net Debt -525M -456M -426M -391M -737M -50B -750M -5.02B -1.97B -24.93B -1.97B -1.93B -82.23B -943M -820M -765M -703M -1.32B -89.9B -1.35B -9.02B -3.53B -44.83B -3.54B -3.46B -148B
Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Employees
915
Date Price Change Volume
04/08/26 USD 482.00 +3.14% 463,895
31/07/26 USD 467.32 -5.23% 795,264
30/07/26 USD 493.11 -9.83% 1,487,716
29/07/26 USD 546.88 +1.50% 356,878
28/07/26 USD 538.80 -2.26% 218,771
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
467.32USD
Average target price
682.93USD
Spread / Average Target
+46.14%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MDGL Stock